SWKH icon

SWK Holdings

14.27 USD
-0.48
3.25%
At close Jun 13, 4:00 PM EDT
1 day
-3.25%
5 days
0.49%
1 month
4.54%
3 months
-12.45%
6 months
-14.14%
Year to date
-10.81%
1 year
-18.32%
5 years
9.77%
10 years
1.21%
 

About: SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

Employees: 26

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

19% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 16

9% more capital invested

Capital invested by funds: $170M [Q4 2024] → $186M (+$16M) [Q1 2025]

0% more funds holding

Funds holding: 52 [Q4 2024] → 52 (+0) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

0.31% less ownership

Funds ownership: 87.56% [Q4 2024] → 87.25% (-0.31%) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$18
26%
upside
Avg. target
$18
26%
upside
High target
$18
26%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Maxim Group
Michael Diana
26%upside
$18
Buy
Maintained
19 May 2025

Financial journalist opinion

Neutral
Seeking Alpha
4 weeks ago
SWK Holdings Corporation (SWKH) Q1 2025 Earnings Call Transcript
SWK Holdings Corporation (NASDAQ:SWKH ) Q1 2025 Earnings Conference Call May 16, 2025 10:00 AM ET Company Participants Susan Xu - Investor Relations Jody Staggs - President and Chief Executive Officer Adam Rice - Chief Financial Officer Conference Call Participants Stefano Latapy - Cannell Capital Operator Good day, everyone. Welcome to the SWK Holdings First Quarter 2025 Conference Call.
SWK Holdings Corporation (SWKH) Q1 2025 Earnings Call Transcript
Neutral
Accesswire
1 month ago
SWK Holdings Corporation Announces Financial Results for First Quarter 2025
Conference Call Scheduled for Friday, May 16, 2025, at 09:00 a.m. CST Corporate Highlights First quarter 2025 GAAP net income was $4.5 million, compared with GAAP net income of $0.5 million for the first quarter 2024.
SWK Holdings Corporation Announces Financial Results for First Quarter 2025
Neutral
Accesswire
1 month ago
SWK Holdings Announces First Quarter 2025 Earnings Release Date and Conference Call
DALLAS, TX / ACCESS Newswire / May 9, 2025 / SWK Holdings Corporation (Nasdaq:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that it will issue its first quarter 2025 earnings results after the market close on Thursday, May 15, 2025. The Company will host a conference call to discuss its corporate and financial results on Friday, May 16, 2025 at 10:00am ET.
SWK Holdings Announces First Quarter 2025 Earnings Release Date and Conference Call
Neutral
Accesswire
2 months ago
SWK Holdings Announces Closing of Royalty Sale and $4.00 Per Share Special Dividend
DALLAS, TX / ACCESS Newswire / April 10, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company, today announced the closing of the previously announced royalty sale to SCOF SPV I, LP, an affiliate of Soleus Capital Management, for total cash proceeds of approximately $34.0 million. In conjunction with the closing, SWK's Board of Directors has declared a special cash dividend of $4.00 per share, payable to all holders of record of the Company's common stock as of April 24, 2025, with a payment date of May 8, 2025.
SWK Holdings Announces Closing of Royalty Sale and $4.00 Per Share Special Dividend
Neutral
Seeking Alpha
2 months ago
SWK Holdings Corporation (SWKH) Q4 2024 Earnings Call Transcript
SWK Holdings Corporation (NASDAQ:SWKH ) Q4 2024 Earnings Conference Call March 20, 2025 10:00 AM ET Company Participants Susan Xu - IR Jody Staggs - President & CEO Adam Rice - CFO Conference Call Participants Operator Greetings. Welcome to the SWK Holdings Fourth Quarter 2024 Conference Call.
SWK Holdings Corporation (SWKH) Q4 2024 Earnings Call Transcript
Neutral
Accesswire
2 months ago
SWK Holdings Announces Monetization of Royalty Portfolio
DALLAS, TX / ACCESS Newswire / March 19, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced the monetization of its royalty portfolio through two transactions. On March 17, 2025, ANI Pharmaceuticals, Inc. exercised its buyout option related to the Iluvien royalty, which resulted in a payment of approximately $17.3 million to SWK.
SWK Holdings Announces Monetization of Royalty Portfolio
Neutral
Accesswire
2 months ago
SWK Holdings Corporation Announces Financial Results for Fourth Quarter 2024
Conference Call Scheduled for Thursday, March 20, 2025, at 09:00 a.m. CST Corporate Highlights Fourth quarter 2024 GAAP net income was $5.9 million, compared with GAAP net income of $2.8 million for the fourth quarter 2023.
SWK Holdings Corporation Announces Financial Results for Fourth Quarter 2024
Neutral
Accesswire
3 months ago
SWK Holdings Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call
DALLAS, TX / ACCESS Newswire / March 13, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that it will issue its fourth quarter and full year 2024 earnings results after the market close on Wednesday, March 19, 2025. The Company will host a conference call to discuss its corporate and financial results on Thursday, March 20, 2025 at 10:00am ET.
SWK Holdings Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call
Neutral
PRNewsWire
4 months ago
ImpediMed Secures $15m Growth Capital Funding
New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif.
ImpediMed Secures $15m Growth Capital Funding
Neutral
Accesswire
5 months ago
SWK Holdings Provides Portfolio Update
DALLAS, TX / ACCESSWIRE / January 6, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update for material events occurring since September 30, 2024. Originations In November, SWK advanced $5.0M to existing borrower Journey Medical to help fund the company's launch of EmrosiTM.
SWK Holdings Provides Portfolio Update
Charts implemented using Lightweight Charts™